Julio A Ramirez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1341800/publications.pdf

Version: 2024-02-01

225 papers	10,080 citations	44069 48 h-index	39675 94 g-index
227 all docs	227 docs citations	227 times ranked	8947 citing authors

#	Article	IF	Citations
1	Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia. Chest, 2022, 161, 927-936.	0.8	22
2	Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia. Respiratory Medicine, 2022, 191, 106714.	2.9	7
3	Mental and physical health profile of Syrian resettled refugees. Primary Health Care Research and Development, 2022, 23, e21.	1.2	2
4	23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms, 2022, 10, 560.	3.6	18
5	Frequency of stool specimen collection and testing for Clostridioides difficile of hospitalized adults and long-term care facility residents with new-onset diarrhea in Louisville, Kentucky. International Journal of Infectious Diseases, 2022, 120, 196-200.	3.3	2
6	Burden of Adults Hospitalized With Group B Streptococcal Infection. Journal of Infectious Diseases, 2021, 224, 1170-1178.	4.0	11
7	Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. ERJ Open Research, 2021, 7, 00736-2020.	2.6	13
8	Is Microthrombosis the Main Pathology in Coronavirus Disease 2019 Severity?â€"A Systematic Review of the Postmortem Pathologic Findings. , 2021, 3, e0427.		29
9	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	5.8	33
10	Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study. Open Forum Infectious Diseases, 2021, 8, ofab135.	0.9	4
11	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	3.2	17
12	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. JAMA - Journal of the American Medical Association, 2021, 326, 46.	7.4	162
13	Clinical Outcomes of Immunocompromised Adults Hospitalized with Pneumococcal Pneumonia: A Case-Control Study. Microorganisms, 2021, 9, 1746.	3.6	0
14	Database Enabled Rapid Seismic Vulnerability Assessment of Bridges. Transportation Research Record, 2021, 2675, 1106-1120.	1.9	2
15	Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Scientific Reports, 2021, 11, 15715.	3.3	15
16	Seeking diagnostic and prognostic biomarkers for childhood bacterial pneumonia in sub-Saharan Africa: study protocol for an observational study. BMJ Open, 2021, 11, e046590.	1.9	0
17	Effectiveness of oseltamivir treatment on clinical failure in hospitalized patients with lower respiratory tract infection. BMC Infectious Diseases, 2021, 21, 1106.	2.9	3
18	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. PLoS ONE, 2021, 16, e0258482.	2.5	2

#	Article	IF	Citations
19	756. Clostridioides difficile Burden of Disease: A Prospective Population-Based Surveillance Study of Hospitalized Adults in Louisville, Kentucky. Open Forum Infectious Diseases, 2021, 8, S475-S476.	0.9	0
20	Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course. Chest, 2020, 157, 34-41.	0.8	29
21	Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes. Journal of the American Geriatrics Society, 2020, 68, 1007-1014.	2.6	25
22	Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010â€“2013. Open Forum Infectious Diseases, 2020, 7, ofaa262.	0.9	9
23	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
24	Response. Chest, 2020, 158, 2703-2704.	0.8	0
25	Discovery and predictive modeling of urine microbiome, metabolite and cytokine biomarkers in hospitalized patients with community acquired pneumonia. Scientific Reports, 2020, 10, 13418.	3.3	12
26	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.8	26
27	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest, 2020, 158, 1008-1016.	0.8	46
28	Community-acquired pneumonia in chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 2020, 33, 173-181.	3.1	24
29	Traumatic Experiences and Mental Health Risk for Refugees. International Journal of Environmental Research and Public Health, 2020, 17, 1943.	2.6	26
30	Socioeconomic Position and the Incidence, Severity, and Clinical Outcomes of Hospitalized Patients With Community-Acquired Pneumonia. Public Health Reports, 2020, 135, 364-371.	2.5	19
31	Patients with Obesity Have Better Long-Term Outcomes after Hospitalization for COPD Exacerbation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 373-377.	1.6	18
32	Frequency of Testing for Clostridioides difficile in Long-Term Care Facilities in Louisville, Kentucky. Infection Control and Hospital Epidemiology, 2020, 41, s445-s445.	1.8	0
33	Frequency of Testing for Clostridioides difficile in Adults Hospitalized with Diarrhea in Louisville, Kentucky. Infection Control and Hospital Epidemiology, 2020, 41, s444-s444.	1.8	2
34	Plasma cysteine/cystine and glutathione/glutathione disulfide redox potentials in HIV and COPD patients. Free Radical Biology and Medicine, 2019, 143, 55-61.	2.9	17
35	Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. Clinical Infectious Diseases, 2019, 69, S33-S39.	5.8	11
36	Predicting the need for ICU admission in community-acquired pneumonia. Respiratory Medicine, 2019, 155, 61-65.	2.9	10

#	Article	IF	Citations
37	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine, 2019, 37, 3352-3361.	3.8	54
38	2195. Incidence of Acute Myocardial Infarction in Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2019, 6, S747-S748.	0.9	1
39	Automated Recovery of Structural Drawing Images Collected from Postdisaster Reconnaissance. Journal of Computing in Civil Engineering, 2019, 33, .	4.7	5
40	Postevent Reconnaissance Image Documentation Using Automated Classification. Journal of Performance of Constructed Facilities, 2019, 33, .	2.0	25
41	Clinical Research in Pneumonia: Role of Artificial Intelligence. The University of Louisville Journal of Respiratory Infections, 2019, 3, 1-4.	0.0	3
42	Current and Future Antivirals Medications to Treat Influenza: Mechanisms of Action. The University of Louisville Journal of Respiratory Infections, 2019, 3, .	0.0	0
43	How can we improve clinical research in pneumonia?. Current Opinion in Pulmonary Medicine, 2018, 24, 220-226.	2.6	1
44	A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. Clinical Infectious Diseases, 2018, 67, 736-742.	5.8	28
45	Googling your hand hygiene data: Using Google Forms, Google Sheets, and R to collect and automate analysis of hand hygiene compliance monitoring. American Journal of Infection Control, 2018, 46, 617-619.	2.3	17
46	Future Research Directions in Pneumonia. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 256-263.	5.6	54
47	The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Infectious Diseases, 2018, 50, 13-20.	2.8	11
48	Methods for computational disease surveillance in infection prevention and control: Statistical process control versus Twitter's anomaly and breakout detection algorithms. American Journal of Infection Control, 2018, 46, 124-132.	2.3	11
49	Influenza and Viral Pneumonia. Clinics in Chest Medicine, 2018, 39, 703-721.	2.1	45
50	Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. Annals of the American Thoracic Society, 2018, 15, 1247-1255.	3.2	6
51	PREDICTING ADMISSION TO THE ICU IN COMMUNITY-ACQUIRED PNEUMONIA. Chest, 2018, 154, 145A.	0.8	0
52	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clinical Infectious Diseases, 2018, 67, 1498-1506.	5.8	98
53	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	2.9	11
54	Clinical Research: From Idea to Publication. The University of Louisville Journal of Respiratory Infections, 2018, 2, .	0.0	0

#	Article	IF	Citations
55	Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP). , 2018, , .		0
56	Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center. American Journal of Infection Control, 2017, 45, 673-676.	2.3	10
57	Long-term Mortality in Hospitalized Patients With Community-Acquired Pneumonia. American Journal of the Medical Sciences, 2017, 353, 421.	1.1	1
58	Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology and Mortality. Open Forum Infectious Diseases, 2017, 4, S571-S571.	0.9	2
59	Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. Diagnostic Microbiology and Infectious Disease, 2017, 89, 294-299.	1.8	11
60	Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulmonary Pharmacology and Therapeutics, 2017, 45, 191-201.	2.6	13
61	Process control charts in infection prevention: Make it simple to make it happen. American Journal of Infection Control, 2017, 45, 216-221.	2.3	11
62	Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Diseases, 2017, 65, 1806-1812.	5.8	366
63	One-Year Mortality in Patients with Community-Acquired Pneumonia. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	4
64	Lung Cytokines and Systemic Inflammation in Patients with COPD. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	5
65	Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.. The University of Louisville Journal of Respiratory Infections, 2017, 1, 3-11.	0.0	13
66	Why a new journal?. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
67	Neutrophil function in elderly patients hospitalized with community-acquired pneumonia.. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
68	The presence of COPD does not influence clinical outcomes in hospitalized patients with community-acquired pneumonia.. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
69	Pneumonia research and the Omics revolution: it is time for pneumOmics.. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
70	Analysis of the local and systemic cytokine response profiles in patients with community-acquired pneumonia. Relationship with disease severity and outcomes.. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	1
71	Clinical & Translational Research in Pneumonia: Defining a Research Agenda for Today and Tomorrow. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
72	Health Profiles of Newly Arriving Refugees In Kentucky, 2016: Data from the University of Louisville Global Health Program. Journal of Refugee & Global Health, 2017, 1, .	0.1	0

#	Article	IF	Citations
73	Using Steroids in Patients with Community-Acquired Pneumonia at the University of Louisville Hospital: Who, What, and When. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	1
74	Level of Recall Bias Regarding Pneumococcal Vaccination History among Adults Hospitalized with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	2
75	Pneumonia Pathogenesis and the Lung Microbiome: Back to the Drawing Board. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.0	0
76	The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. Annals of the American Thoracic Society, 2016, 13, 1519-1526.	3.2	69
77	Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study. Pneumonia (Nathan Qld), 2016, 8, 8.	6.1	11
78	Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 819-828.	2.1	22
79	Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes. Journal of Critical Care, 2016, 35, 29-32.	2.2	28
80	Comparing posteroanterior with lateral and anteroposterior chest radiography in the initial detection of parapneumonic effusions. American Journal of Emergency Medicine, 2016, 34, 2402-2407.	1.6	4
81	Disinfectant sprays versus wipes: Applications in behavioral health. American Journal of Infection Control, 2016, 44, 1698-1699.	2.3	2
82	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	3.2	54
83	Kawasaki-like disease (KLD) in an adult with congenital HIV infection. HIV and AIDS Review, 2016, 15, 47-50.	0.2	0
84	Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. European Respiratory Review, 2016, 25, 178-188.	7.1	121
85	Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Medical Informatics and Decision Making, 2016, 16, 34.	3.0	22
86	Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study. Lung, 2016, 194, 155-162.	3.3	8
87	Tuberculosis is always a possibility (even in the intensive care unit). Revista Brasileira De Terapia Intensiva, 2016, 28, 97-9.	0.3	2
88	Real-time enrollment dashboard for multisite clinical trials. Contemporary Clinical Trials Communications, 2015, 1, 17-21.	1.1	16
89	The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study. Pneumonia (Nathan Qld), 2015, 6, 83-89.	6.1	1
90	An iterative workflow for creating biomedical visualizations using Inkscape and D3.js. BMC Bioinformatics, 2015, 16, .	2.6	2

#	Article	IF	Citations
91	Understanding why low-risk patients accept vaccines: a socio-behavioral approach. BMC Research Notes, 2015, 8, 813.	1.4	7
92	Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia. ERJ Open Research, 2015, 1, 00020-2015.	2.6	26
93	Addressing the challenges of refugee health: Experiences from the University of Louisville interprofessional refugee immunization clinic. Journal of Nursing Education and Practice, 2015, 5, .	0.2	0
94	How to choose the duration of antibiotic therapy in patients with pneumonia. Current Opinion in Infectious Diseases, 2015, 28, 177-184.	3.1	17
95	Visual grids for managing data completeness in clinical research datasets. Journal of Biomedical Informatics, 2015, 54, 337-344.	4.3	4
96	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respiratory Medicine, 2015, 109, 743-750.	2.9	29
97	Adherence With National Guidelines in Hospitalized Patients With Community-acquired Pneumonia: Results From the CAPO Study in Venezuela. Archivos De Bronconeumologia, 2015, 51, 163-168.	0.8	3
98	Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae. American Journal of Infection Control, 2015, 43, 380-382.	2.3	5
99	What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?. Current Opinion in Infectious Diseases, 2015, 28, 164-170.	3.1	8
100	Possible role of tetracyclines on decreasing the accelerated aging process of well-controlled HIV patients on antiretroviral therapy. HIV and AIDS Review, 2015, 14, 133-137.	0.2	1
101	Characteristics associated with clinician diagnosis of aspiration pneumonia: A descriptive study of afflicted patients and their outcomes. Journal of Hospital Medicine, 2015, 10, 90-96.	1.4	52
102	Cumplimiento con las guÃas nacionales en pacientes hospitalizados con neumonÃa adquirida en la comunidad: resultados del Estudio Capo en Venezuela. Archivos De Bronconeumologia, 2015, 51, 163-168.	0.8	4
103	Distribution of PCV13 Pneumococcal Serotypes in Patients With Community-Acquired Pneumonia Presenting at 20 United States Hospitals. Open Forum Infectious Diseases, 2015, 2, .	0.9	2
104	Risk factors for pulmonary tuberculosis in community-acquired pneumonia. European Respiratory Journal, 2014, 43, 1214-1214.	6.7	0
105	Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Critical Care, 2014, 18, R118.	5.8	37
106	Cardiac diseases complicating community-acquired pneumonia. Current Opinion in Infectious Diseases, 2014, 27, 295-301.	3.1	41
107	A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia. Respiratory Care, 2014, 59, 1078-1085.	1.6	41
108	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	3.6	39

#	Article	IF	Citations
109	The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine, 2014, 32, 2198-2203.	3.8	42
110	Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. Inflammation, 2014, 37, 1158-1166.	3.8	51
111	The value of ready-to-use disinfectant wipes: Compliance, employee time, and costs. American Journal of Infection Control, 2014, 42, 329-330.	2.3	20
112	Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review. Respiratory Medicine, 2014, 108, 1569-1580.	2.9	38
113	Evaluation of the effectiveness of improved hydrogen peroxide in the operating room. American Journal of Infection Control, 2014, 42, 1004-1005.	2.3	4
114	Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. European Respiratory Journal, 2014, 43, 178-184.	6.7	23
115	The role of infection prevention conferences to build and maintain knowledge-sharing networks: A longitudinal evaluation. American Journal of Infection Control, 2014, 42, 209-211.	2.3	9
116	A single genotype of Acinetobacter baumannii expresses multiple antibiotic susceptibility phenotypes. American Journal of Infection Control, 2014, 42, 556-558.	2.3	1
117	Ruling Out Legionella in Community-acquired Pneumonia. American Journal of Medicine, 2014, 127, 1010.e11-1010.e19.	1.5	39
118	Nontuberculous mycobacterial pulmonary infections. , 2014, , 128-137.		1
119	Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. European Respiratory Journal, 2013, 41, 1135-1140.	6.7	20
120	Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine, 2013, 107, 1101-1111.	2.9	59
121	Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. International Journal of Infectious Diseases, 2013, 17, e293-e298.	3.3	27
122	Absence of Gender-Based Differences in Outcome of Patients with Hospital-Acquired Pneumonia. Journal of Women's Health, 2013, 22, 1069-1075.	3.3	11
123	Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. International Journal of Infectious Diseases, 2013, 17, e76-e83.	3.3	163
124	Clinical Scoring Tools. Infectious Disease Clinics of North America, 2013, 27, 33-48.	5.1	8
125	What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia?. Infectious Disease Clinics of North America, 2013, 27, 205-210.	5.1	10
126	Axial Failure of Reinforced Concrete Columns Damaged by Shear Reversals. Journal of Structural Engineering, 2013, 139, 1172-1180.	3.4	23

#	Article	IF	Citations
127	Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. International Journal of Infectious Diseases, 2013, 17, e398-e403.	3.3	27
128	Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?. European Respiratory Journal, 2013, 41, 5-6.	6.7	4
129	Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. European Respiratory Journal, 2013, 42, 742-749.	6.7	34
130	Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1756-1762.	3.2	208
131	Phenotypic Differences in Virulence and Immune Response in Closely Related Clinical Isolates of Influenza A 2009 H1N1 Pandemic Viruses in Mice. PLoS ONE, 2013, 8, e56602.	2.5	16
132	Global Changes in the Epidemiology of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 213-219.	2.1	30
133	Analysis of Pathogen and Host Factors Related to Clinical Outcomes in Patients with Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus. Journal of Clinical Microbiology, 2012, 50, 1640-1644.	3.9	31
134	Septicemia in Patients With AIDS Admitted to a University Health System: A Case Series of Eighty-Three Patients. Journal of the American Board of Family Medicine, 2012, 25, 318-322.	1.5	7
135	Antigens of persistentChlamydia pneumoniaewithin coronary atheroma from patients undergoing heart transplantation. Journal of Clinical Pathology, 2012, 65, 171-177.	2.0	10
136	Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky. American Journal of Infection Control, 2012, 40, 440-445.	2.3	11
137	Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin. BMC Infectious Diseases, 2012, 12, 159.	2.9	9
138	Knowledge sharing among healthcare infection preventionists: the impact of public health professionals in a rural state. BMC Research Notes, 2012, 5, 387.	1.4	2
139	Incidence of Nephrotoxicity and Association With Vancomycin Use in Intensive Care Unit Patients With Pneumonia: Retrospective Analysis of the IMPACT-HAP Database. Clinical Therapeutics, 2012, 34, 149-157.	2.5	139
140	The Use of Large Databases to Study Pneumonia: What is Their Value?. Clinics in Chest Medicine, 2011, 32, 481-489.	2.1	3
141	Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. International Journal of Antimicrobial Agents, 2011, 38, 291-295.	2.5	44
142	Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respiratory Medicine, 2011, 105, 1732-1738.	2.9	35
143	Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infectious Diseases, The, 2011, 11, 181-189.	9.1	210
144	Treatment of hospital-acquired pneumonia â€“ Authors' Reply. Lancet Infectious Diseases, The, 2011, 11, 731-732.	9.1	2

#	Article	IF	Citations
145	Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Critical Care, 2011, 15, R38.	5.8	29
146	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. International Journal of Infectious Diseases, 2011, 15, e822-e827.	3.3	9
147	The Challenge of Predicting Influenza. Frontiers in Microbiology, 2011, 2, 45.	3.5	0
148	Ventilator-associated pneumonia in critically ill stroke patients: Frequency, risk factors, and outcomes. Journal of Critical Care, 2011, 26, 273-279.	2.2	47
149	How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Medical Research Methodology, 2011, 11, 144.	3.1	106
150	Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene. Clinical Infectious Diseases, 2011, 53, 766-771.	5.8	37
151	Pneumonia and Mortality Beyond Hospital Discharge in Elderly Patients: Response. Chest, 2011, 139, 474-475.	0.8	2
152	Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2011, 140, 482-488.	0.8	41
153	Thrombocytopenia and Thrombocytosis at Time of Hospitalization Predict Mortality in Patients With Community-Acquired Pneumonia. Chest, 2010, 137, 416-420.	0.8	129
154	Relationship of Vancomycin Minimum Inhibitory Concentration to Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Hospital-Acquired, Ventilator-Associated, or Health-care-Associated Pneumonia. Chest, 2010, 138, 1356-1362.	0.8	95
155	Decrease in Long-term Survival for Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 279-283.	0.8	90
156	Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response. Chest, 2010, 138, 1279-1280.	0.8	1
157	Methicillin-resistant Staphylococcus aureus resistance to nonâ€“Î²-lactam antimicrobials in the United States from 1996 to 2008. Diagnostic Microbiology and Infectious Disease, 2010, 67, 395-398.	1.8	20
158	Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine, 2010, 104, 1736-1743.	2.9	28
159	Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. International Journal of Infectious Diseases, 2010, 14, e22-e27.	3.3	27
160	Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. International Journal of Infectious Diseases, 2010, 14, e84-e85.	3.3	30
161	Clinical and economic burden of pneumonia among adults in Latin America. International Journal of Infectious Diseases, 2010, 14, e852-e856.	3.3	58
162	Simultaneous Shear and Axial Failures of Reinforced Concrete Columns. , 2009, , .		5

#	Article	IF	Citations
163	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. Archives of Internal Medicine, 2009, 169, 1515.	3.8	106
164	Predicting Mortality in Patients with Ventilatorâ€Associated Pneumonia: The APACHE II Score versus the New IBMPâ€10 Score. Clinical Infectious Diseases, 2009, 49, 72-77.	5.8	32
165	Performance of School Buildings in Turkey During the 1999 DÃ¼zce and the 2003 BingÃ¶l Earthquakes. Earthquake Spectra, 2009, 25, 239-256.	3.1	28
166	A practical iterative procedure to estimate seismic-induced deformations of shallow rectangular structures. Canadian Geotechnical Journal, 2008, 45, 923-938.	2.8	72
167	Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis, 2008, 199, 154-161.	0.8	52
168	Acute Myocardial Infarction in Hospitalized Patients with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 182-187.	5.8	166
169	Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2008, 134, 955-962.	0.8	112
170	SMARTâ€COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 375-384.	5.8	458
171	The Presence of Pneumococcal Bacteremia Does Not Influence Clinical Outcomes in Patients With Community-Acquired Pneumonia. Chest, 2008, 133, 618-624.	0.8	80
172	A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1086-1093.	5.6	209
173	Atypical Coverage for Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1289-1290.	5.6	0
174	A process for analysis of sentinel events due to health careâ€“associated infection. American Journal of Infection Control, 2007, 35, 501-507.	2.3	8
175	Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan. Journal of Infection, 2007, 55, 214-219.	3.3	15
176	Controlling multiple-drug-resistant organisms at the hospital level. Expert Opinion on Pharmacotherapy, 2006, 7, 1449-1455.	1.8	6
177	Improving Antimicrobial Use in the Hospital Setting by Providing Usage Feedback to Prescribing Physicians. Infection Control and Hospital Epidemiology, 2006, 27, 378-382.	1.8	54
178	Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection. BMC Infectious Diseases, 2006, 6, 152.	2.9	16
179	Antibiotic therapy of hospitalized patients with community-acquired pneumonia: an international perspective from the CAPO Cohort Study. The Journal of the Kentucky Medical Association, 2006, 104, 513-7.	0.1	2
180	Multicenter, Multinational Observational Studies: A New Approach to Studying Community-acquired Pneumonia. Respiratory Care Clinics of North America, 2005, 11, 35-44.	0.5	6

#	Article	IF	Citations
181	ACI 318 Structural Concrete Building Code: The Need for Member Size Factor on the Shear Strength of Beams and One-Way Slabs. , 2005, , 1.		1
182	Worldwide Perspective of the Quality of Care Provided to Hospitalized Patients with Community-Acquired Pneumonia: Results from the CAPO International Cohort Study. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 543-552.	2.1	19
183	Improving Antimicrobial Use: Longitudinal Assessment of an Antimicrobial Team Including a Clinical Pharmacist. Journal of Managed Care Pharmacy, 2004, 10, 152-158.	2.2	18
184	Legionnaires Disease and the Updated IDSA Guidelines for Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2004, 39, 1734-1737.	5.8	14
185	Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest, 2004, 125, 1888-1901.	0.8	92
186	Effects of Fluoroquinolones on the Migration of Human Phagocytes through Chlamydia pneumoniae -Infected and Tumor Necrosis Factor Alpha-Stimulated Endothelial Cells. Antimicrobial Agents and Chemotherapy, 2004, 48, 2538-2543.	3.2	31
187	Processes of care for community-acquired pneumonia. Infectious Disease Clinics of North America, 2004, 18, 843-859.	5.1	6
188	Community-acquired pneumonia in adults. Primary Care - Clinics in Office Practice, 2003, 30, 155-171.	1.6	9
189	Guidelines for Community-Acquired Pneumonia Within Disease Management Programs. Disease Management and Health Outcomes, 2003, 11, 33-43.	0.4	0
190	Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy, 2003, 51, 1025-1028.	3.0	21
191	Hospitalization for Community-Acquired Pneumonia. Chest, 2003, 124, 121-124.	0.8	102
192	Effect of Macrolide Antibiotics on Human Endothelial Cells Activated byChlamydia pneumoniaeInfection and Tumor Necrosis Factorâ€"Î±. Journal of Infectious Diseases, 2002, 185, 1631-1636.	4.0	34
193	Proteomic Analysis of Differentially Expressed Chlamydia pneumoniae Genes during Persistent Infection of HEp-2 Cells. Infection and Immunity, 2002, 70, 2976-2981.	2.2	78
194	The Use of Heteroduplex Analysis of Polymerase Chain Reaction Products to Support the Possible Transmission ofLegionella pneumophilaFrom a Malfunctioning Automobile Air Conditioner. Infection Control and Hospital Epidemiology, 2002, 23, 145-147.	1.8	7
195	Community-Acquired Pneumonia Due to Chlamydia pneumoniae. , 2002, , 501-509.		1
196	Guidelines for community-acquired pneumonia in the US and Canada: A practical approach to antibiotic selection. Comprehensive Therapy, 2002, 28, 201-207.	0.2	3
197	Guidelines for the Management of Adults with Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1730-1754.	5.6	2,041
198	Managing Antiinfective Therapy of Community-Acquired Pneumonia in the Hospital Setting: Focus on Switch Therapy. Pharmacotherapy, 2001, 21, 79S-82S.	2.6	14

#	Article	IF	Citations
199	Early Switch From Intravenous to Oral Antibiotics in Hospitalized Patients With Bacteremic Community-Acquired Streptococcus pneumoniae Pneumonia. Archives of Internal Medicine, 2001, 161, 848.	3.8	107
200	Characterization of Chlamydia pneumoniae Persistence in HEp-2 Cells Treated with Gamma Interferon. Infection and Immunity, 2001, 69, 7927-7932.	2.2	72
201	Inhibition of oxidative burst and chemotaxis in human phagocytes by Legionella pneumophila zinc metalloprotease. Journal of Medical Microbiology, 2001, 50, 517-525.	1.8	18
202	Inhibition of Chlamydia pneumoniaeReplication in Human Aortic Smooth Muscle Cells by Gamma Interferon-Induced Indoleamine 2,3-Dioxygenase Activity. Infection and Immunity, 2000, 68, 6478-6481.	2.2	60
203	Requirement for NF-Î°B in Transcriptional Activation of Monocyte Chemotactic Protein 1 by Chlamydia pneumoniae in Human Endothelial Cells. Infection and Immunity, 2000, 68, 4282-4288.	2.2	63
204	Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2000, 44, 1796-1802.	3.2	69
205	Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge. Archives of Internal Medicine, 1999, 159, 2449.	3.8	204
206	Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clinical Therapeutics, 1999, 21, 103-117.	2.5	53
207	Infection of Human Endothelial Cells with Chlamydia pneumoniae Stimulates Transendothelial Migration of Neutrophils and Monocytes. Infection and Immunity, 1999, 67, 1323-1330.	2.2	111
208	Switch Therapy with Î²-Lactam/Î²-Lactamase Inhibitors in Patients with Community-Acquired Pneumonia. Annals of Pharmacotherapy, 1998, 32, S22-S26.	1.9	20
209	Characterization of a Strain of Chlamydia pneumoniae Isolated from a Coronary Atheroma by Analysis of the omp1 Gene and Biological Activity in Human Endothelial Cells. Infection and Immunity, 1998, 66, 1370-1376.	2.2	83
210	Reduction in Tuberculin Skin-Test Conversion Rate after Improved Adherence to Tuberculosis Isolation. Infection Control and Hospital Epidemiology, 1997, 18, 575-576.	1.8	5
211	Community-Acquired Pneumonia in the Elderly Reply. Southern Medical Journal, 1997, 90, 863-864.	0.7	0
212	Community-Acquired Pneumonia in the Elderly: Association of Mortality With Lack of Fever and Leukocytosis. Southern Medical Journal, 1997, 90, 296-298.	0.7	91
213	Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagnostic Microbiology and Infectious Disease, 1996, 24, 7-14.	1.8	108
214	Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis. Annals of Internal Medicine, 1996, 125, 979.	3.9	445
215	A Case of Concurrent Lyme Meningitis with Ehrlichiosis. Scandinavian Journal of Infectious Diseases, 1996, 28, 527-528.	1.5	10
216	Switch Therapy in Adult Patients with Pneumonia. Clinical Pulmonary Medicine, 1995, 2, 327-333.	0.3	28

#	Article	IF	Citations
217	Early Switch From Intravenous to Oral Cephalosporins in the Treatment of Hospitalized Patients With Community-Acquired Pneumonia. Archives of Internal Medicine, 1995, 155, 1273.	3.8	114
218	Switch therapy in community-acquried pneumonia. Diagnostic Microbiology and Infectious Disease, 1995, 22, 219-223.	1.8	50
219	Advances in antibiotic use: Switch therapy. Current Therapeutic Research, 1994, 55, 30-34.	1.2	7
220	A Randomised Comparative Trial of Aztreonam Plus Cefazolin versus Ceftazidime for the Treatment of Nosocomial Pneumonia. Drug Investigation, 1994, 7, 117-126.	0.6	4
221	TB Test Results May Be Skewed. Infection Control and Hospital Epidemiology, 1993, 14, 192-193.	1.8	0
222	Killing of Legionella pneumophila by nitric oxide in Î³-interferon-activated macrophages. Journal of Leukocyte Biology, 1992, 52, 625-629.	3.3	85
223	Increased Rate of Tuberculin Skin Test Conversion among Workers at a University Hospital. Infection Control and Hospital Epidemiology, 1992, 13, 579-581.	1.8	28
224	Increased Rate of Tuberculin Skin Test Conversion Among Workers at a University Hospital. Infection Control and Hospital Epidemiology, 1992, 13, 579-581.	1.8	21
225	Combination antibiotic therapy and synergy in HAP and VAP. , 0, , 302-311.		0